ESMO 2025

from OncoPharm · host John Bossaer

This week's episode recaps some highlights from ESMO 2025: 1. Destiny-Breast05: T-DXd > T-DM1 in persistent HER2+ disease after neoadjuvant chemo + surgery 2. Keynote-905: Neoadjuvant Enfortumab Vedotin + pembro in cisplatin-ineligible bladder cancer 3. POTOMAC: Durvalumab + BCG in non-muscle invasive bladder cancer 4. IMvigor011: ctDNA-guided adjuvant atezolizumab in bladder cancer 5. Dynamic-III: ctDNA guide de-escalation or escalation of chemotherapy in stage III colon cancer 6. HARMONi-6: an excuse to talk about ivonescimab, a bispecific antibody unlike any other currently FDA approved

Episode metadata supplied by the publisher feed · Published Oct 23, 2025

Embed this episode

Attribution link and audio player

Ready to play

ESMO 2025

0:00 24:43

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncoPharm?

This episode is 24 minutes long.

When was this OncoPharm episode published?

This episode was published on October 23, 2025.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!